Free Trial
→ Distracted Americans set to miss out on quadrillions (From Brownstone Research) (Ad)tc pixel Free RTW Stock Alerts

RTW Biotech Opportunities (RTW) Competitors

RTW Biotech Opportunities logo
GBX 2.18 +0.07 (+3.32%)
As of 11:02 AM Eastern
Compare

RTW vs. CIP, PGIT, DNE, ADAM, and VENC

Should you buy RTW Biotech Opportunities stock or one of its competitors? MarketBeat compares RTW Biotech Opportunities with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RTW Biotech Opportunities include CIP Merchant Capital (CIP), Premier Global Infrastructure Trust PLC (PGIT.L) (PGIT), Dunedin Enterprise Investment Trust (DNE), Jade Road Investments (ADAM), and Ventus VCT C (VENC). These companies are all part of the "asset management" industry.

How does RTW Biotech Opportunities compare to CIP Merchant Capital?

RTW Biotech Opportunities (LON:RTW) and CIP Merchant Capital (LON:CIP) are both small-cap asset management industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

RTW Biotech Opportunities has a net margin of 95.03% compared to CIP Merchant Capital's net margin of 0.00%. RTW Biotech Opportunities' return on equity of 34.38% beat CIP Merchant Capital's return on equity.

Company Net Margins Return on Equity Return on Assets
RTW Biotech Opportunities95.03% 34.38% -0.47%
CIP Merchant Capital N/A N/A N/A

In the previous week, RTW Biotech Opportunities had 1 more articles in the media than CIP Merchant Capital. MarketBeat recorded 1 mentions for RTW Biotech Opportunities and 0 mentions for CIP Merchant Capital. RTW Biotech Opportunities' average media sentiment score of 1.22 beat CIP Merchant Capital's score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the media.

Company Overall Sentiment
RTW Biotech Opportunities Positive
CIP Merchant Capital Neutral

11.3% of RTW Biotech Opportunities shares are held by institutional investors. 0.6% of RTW Biotech Opportunities shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

RTW Biotech Opportunities has higher revenue and earnings than CIP Merchant Capital. CIP Merchant Capital is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RTW Biotech Opportunities£250.89M0.03£14.09B£63.000.03
CIP Merchant Capital£8.87M0.00N/A£13.70N/A

Summary

RTW Biotech Opportunities beats CIP Merchant Capital on 8 of the 10 factors compared between the two stocks.

How does RTW Biotech Opportunities compare to Premier Global Infrastructure Trust PLC (PGIT.L)?

Premier Global Infrastructure Trust PLC (PGIT.L) (LON:PGIT) and RTW Biotech Opportunities (LON:RTW) are both small-cap asset management industry companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

RTW Biotech Opportunities has a net margin of 95.03% compared to Premier Global Infrastructure Trust PLC (PGIT.L)'s net margin of 0.00%. RTW Biotech Opportunities' return on equity of 34.38% beat Premier Global Infrastructure Trust PLC (PGIT.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Premier Global Infrastructure Trust PLC (PGIT.L)N/A N/A N/A
RTW Biotech Opportunities 95.03%34.38%-0.47%

11.3% of RTW Biotech Opportunities shares are held by institutional investors. 0.6% of RTW Biotech Opportunities shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, RTW Biotech Opportunities had 1 more articles in the media than Premier Global Infrastructure Trust PLC (PGIT.L). MarketBeat recorded 1 mentions for RTW Biotech Opportunities and 0 mentions for Premier Global Infrastructure Trust PLC (PGIT.L). RTW Biotech Opportunities' average media sentiment score of 1.22 beat Premier Global Infrastructure Trust PLC (PGIT.L)'s score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the news media.

Company Overall Sentiment
Premier Global Infrastructure Trust PLC (PGIT.L) Neutral
RTW Biotech Opportunities Positive

RTW Biotech Opportunities has higher revenue and earnings than Premier Global Infrastructure Trust PLC (PGIT.L). Premier Global Infrastructure Trust PLC (PGIT.L) is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Premier Global Infrastructure Trust PLC (PGIT.L)-£2.54M0.00N/A-£40.70N/A
RTW Biotech Opportunities£250.89M0.03£14.09B£63.000.03

Summary

RTW Biotech Opportunities beats Premier Global Infrastructure Trust PLC (PGIT.L) on 9 of the 10 factors compared between the two stocks.

How does RTW Biotech Opportunities compare to Dunedin Enterprise Investment Trust?

RTW Biotech Opportunities (LON:RTW) and Dunedin Enterprise Investment Trust (LON:DNE) are both small-cap financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

RTW Biotech Opportunities has a net margin of 95.03% compared to Dunedin Enterprise Investment Trust's net margin of 74.24%. RTW Biotech Opportunities' return on equity of 34.38% beat Dunedin Enterprise Investment Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
RTW Biotech Opportunities95.03% 34.38% -0.47%
Dunedin Enterprise Investment Trust 74.24%3.62%2.87%

11.3% of RTW Biotech Opportunities shares are owned by institutional investors. Comparatively, 32.6% of Dunedin Enterprise Investment Trust shares are owned by institutional investors. 0.6% of RTW Biotech Opportunities shares are owned by insiders. Comparatively, 68.6% of Dunedin Enterprise Investment Trust shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, RTW Biotech Opportunities had 1 more articles in the media than Dunedin Enterprise Investment Trust. MarketBeat recorded 1 mentions for RTW Biotech Opportunities and 0 mentions for Dunedin Enterprise Investment Trust. RTW Biotech Opportunities' average media sentiment score of 1.22 beat Dunedin Enterprise Investment Trust's score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the media.

Company Overall Sentiment
RTW Biotech Opportunities Positive
Dunedin Enterprise Investment Trust Neutral

RTW Biotech Opportunities has higher revenue and earnings than Dunedin Enterprise Investment Trust. Dunedin Enterprise Investment Trust is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RTW Biotech Opportunities£250.89M0.03£14.09B£63.000.03
Dunedin Enterprise Investment Trust£1.99M0.00£1.56M£28.41N/A

RTW Biotech Opportunities has a beta of 1.1536776, meaning that its share price is 15% more volatile than the broader market. Comparatively, Dunedin Enterprise Investment Trust has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Summary

RTW Biotech Opportunities beats Dunedin Enterprise Investment Trust on 8 of the 12 factors compared between the two stocks.

How does RTW Biotech Opportunities compare to Jade Road Investments?

RTW Biotech Opportunities (LON:RTW) and Jade Road Investments (LON:ADAM) are both small-cap asset management industry companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

RTW Biotech Opportunities has higher revenue and earnings than Jade Road Investments. Jade Road Investments is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RTW Biotech Opportunities£250.89M0.03£14.09B£63.000.03
Jade Road InvestmentsN/AN/AN/A-£3.40N/A

11.3% of RTW Biotech Opportunities shares are owned by institutional investors. 0.6% of RTW Biotech Opportunities shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

RTW Biotech Opportunities has a net margin of 95.03% compared to Jade Road Investments' net margin of 0.00%. RTW Biotech Opportunities' return on equity of 34.38% beat Jade Road Investments' return on equity.

Company Net Margins Return on Equity Return on Assets
RTW Biotech Opportunities95.03% 34.38% -0.47%
Jade Road Investments N/A N/A N/A

In the previous week, RTW Biotech Opportunities had 1 more articles in the media than Jade Road Investments. MarketBeat recorded 1 mentions for RTW Biotech Opportunities and 0 mentions for Jade Road Investments. RTW Biotech Opportunities' average media sentiment score of 1.22 beat Jade Road Investments' score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the media.

Company Overall Sentiment
RTW Biotech Opportunities Positive
Jade Road Investments Neutral

Summary

RTW Biotech Opportunities beats Jade Road Investments on 9 of the 10 factors compared between the two stocks.

How does RTW Biotech Opportunities compare to Ventus VCT C?

RTW Biotech Opportunities (LON:RTW) and Ventus VCT C (LON:VENC) are both small-cap asset management industry companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

RTW Biotech Opportunities has higher revenue and earnings than Ventus VCT C. Ventus VCT C is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RTW Biotech Opportunities£250.89M0.03£14.09B£63.000.03
Ventus VCT C£8.35M0.00N/A£21.60N/A

11.3% of RTW Biotech Opportunities shares are owned by institutional investors. 0.6% of RTW Biotech Opportunities shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

RTW Biotech Opportunities has a net margin of 95.03% compared to Ventus VCT C's net margin of 0.00%. RTW Biotech Opportunities' return on equity of 34.38% beat Ventus VCT C's return on equity.

Company Net Margins Return on Equity Return on Assets
RTW Biotech Opportunities95.03% 34.38% -0.47%
Ventus VCT C N/A N/A N/A

In the previous week, RTW Biotech Opportunities had 1 more articles in the media than Ventus VCT C. MarketBeat recorded 1 mentions for RTW Biotech Opportunities and 0 mentions for Ventus VCT C. RTW Biotech Opportunities' average media sentiment score of 1.22 beat Ventus VCT C's score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the media.

Company Overall Sentiment
RTW Biotech Opportunities Positive
Ventus VCT C Neutral

Summary

RTW Biotech Opportunities beats Ventus VCT C on 8 of the 10 factors compared between the two stocks.

Get RTW Biotech Opportunities News Delivered to You Automatically

Sign up to receive the latest news and ratings for RTW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RTW vs. The Competition

Export
MetricRTW Biotech OpportunitiesAsset Management IndustryFinancial SectorLON Exchange
Market Cap£7.06M£2.37B£5.75B£2.78B
Dividend YieldN/A5.99%5.27%6.09%
P/E Ratio0.0325.2115.77366.07
Price / Sales0.031,953.79925.2088,395.03
Price / Cash0.3260.1790.3227.89
Price / Book0.011.354.397.70
Net Income£14.09B£265.53M£1.15B£5.89B
7 Day PerformanceN/A-0.20%0.21%0.59%
1 Month Performance2.40%2.33%2.05%2.54%
1 Year Performance88.74%13.38%21.78%87.53%

RTW Biotech Opportunities Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RTW
RTW Biotech Opportunities
N/AGBX 2.18
+3.3%		N/A+77.3%£7.06M£250.89M0.034,971
CIP
CIP Merchant Capital
N/AN/AN/AN/A£27.50M£8.87M3.65N/A
PGIT
Premier Global Infrastructure Trust PLC (PGIT.L)
N/AN/AN/AN/A£26.23M-£2.54MN/AN/A
DNE
Dunedin Enterprise Investment Trust
N/AN/AN/AN/A£26.15M£1.99M16.72N/A
ADAM
Jade Road Investments
N/AN/AN/AN/A£25.17MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:RTW) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
Microscopic Footage Shows Immune Cells Attacking Cancer
Early human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using it...
Market Tactic | Sponsoredtc pixel
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...
Brownstone Research | Sponsoredtc pixel